Systematic review on pleurectomy/decortication in the multimodality treatment of malignant pleural mesothelioma

被引：0

作者：

Sestini, Stefano ^{[1
]}

Bills, Andrea ^{[1
]}

Okiror, Lawrence ^{[2
]}

Gisabella, Mara ^{[1
]}

Pastorino, Ugo ^{[1
]}

机构：

[1] Fondazione IRCCS Ist Nazl Tumori, Dept Thorac Surg, Via G Venezian 1, Milan, Italy

[2] Birmingham Heartlands Hosp, Dept Thorac Surg, Birmingham, W Midlands, England

来源：

LUNG CANCER MANAGEMENT | 2014年 / 3卷 / 04期

关键词：

extrapleural pneumonectomy; malignant pleural mesothelioma; multimodality treatment; overall survival; pleurectomy/decortication;

D O I：

10.2217/LMT.14.26

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Malignant pleural mesothelioma (MPM) is an aggressive tumor of pleural membranes with a dismal prognosis. Following diagnosis survival is usually less than 12 months. The treatment is therefore very often palliative. In selected cases with early stage disease surgical resection is possible. Several studies have now shown that combination treatment with chemotherapy (CHT), radiotherapy (RT) and radical surgery lead to an increased overall survival (OS). This review analyzes the long-term results of the two different types of radical surgery included in the multimodality treatment: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). Recent studies have shown P/D to have less morbidity with comparable or better OS compared with EPP while enabling more patients to complete multimodality treatment.

引用

页码：345 / 354

页数：10

共 39 条

[31]

Srivastava Vivek, 2009, Interact Cardiovasc Thorac Surg, V8, P454, DOI 10.1510/icvts.2008.197160

[32] Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies [J].

Sugarbaker, DJ ;

Jaklitsch, MT ;

Bueno, R ;

Richards, W ;

Lukanich, J ;

Mentzer, SJ ;

Colson, Y ;

Linden, P ;

Chang, M ;

Capalbo, L ;

Oldread, E ;

Neragi-Miandoab, S ;

Swanson, SJ ;

Zellos, LS .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 128 (01) :138-146

[33] Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients [J].

Sugarbaker, DJ ;

Flores, RM ;

Jaklitsch, MT ;

Richards, WG ;

Strauss, GM ;

Carson, JM ;

DeCamp, MM ;

Swanson, SJ ;

Bueno, R ;

Lukanich, JM ;

Baldini, EH ;

Mentzer, SJ .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (01) :54-63

[34] EXTRAPLEURAL PNEUMONECTOMY IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA [J].

SUGARBAKER, DJ ;

MENTZER, SJ ;

STRAUSS, G .

ANNALS OF THORACIC SURGERY, 1992, 54 (05) :941-946

[35] Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study [J].

Treasure, Tom ;

Lang-Lazdunski, Loic ;

Waller, David ;

Bliss, Judith M. ;

Tan, Carol ;

Entwisle, James ;

Snee, Michael ;

O'Brien, Mary ;

Thomas, Gill ;

Senan, Suresh ;

O'Byrne, Ken ;

Kilburn, Lucy S. ;

Spicer, James ;

Landau, David ;

Edwards, John ;

Coombes, Gill ;

Darlison, Liz ;

Peto, Julian .

LANCET ONCOLOGY, 2011, 12 (08) :763-772

[36] Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial [J].

Van Schil, P. E. ;

Baas, P. ;

Gaafar, R. ;

Maat, A. P. ;

Van de Pol, M. ;

Hasan, B. ;

Klomp, H. M. ;

Abdelrahman, A. M. ;

Welch, J. ;

van Meerbeeck, J. P. .

EUROPEAN RESPIRATORY JOURNAL, 2010, 36 (06) :1362-1369

[37] Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [J].

Vogelzang, NJ ;

Rusthoven, JJ ;

Symanowski, J ;

Denham, C ;

Kaukel, E ;

Ruffie, P ;

Gatzemeier, U ;

Boyer, M ;

Emri, S ;

Manegold, C ;

Niyikiza, C ;

Paoletti, P .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2636-2644

[38] Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma [J].

Weder, W. ;

Stahel, R. A. ;

Bernhard, J. ;

Bodis, S. ;

Vogt, P. ;

Ballabeni, P. ;

Lardinois, D. ;

Betticher, D. ;

Schmid, R. ;

Stupp, R. ;

Ris, H. B. ;

Jermann, M. ;

Mingrone, W. ;

Roth, A. D. ;

Spiliopoulos, A. .

ANNALS OF ONCOLOGY, 2007, 18 (07) :1196-1202

[39] The MARS feasibility trial: conclusions not supported by data [J].

Weder, Walter ;

Stahel, Rolf A. ;

Baas, Paul ;

Dafni, Urania ;

de Perrot, Marc ;

McCaughan, Brian C. ;

Nakano, Takashi ;

Pass, Harvey I. ;

Robinson, Bruce W. S. ;

Rusch, Valerie W. ;

Sugarbaker, David J. ;

van Zandwijk, Nico .

LANCET ONCOLOGY, 2011, 12 (12) :1093-1094

← 1 2 3 4 →